nach oben

Der Nervenarzt

Erschienen in:

01.04.2010 | Übersichten

HIV-assoziierte Neuropathien

verfasst von: Dr. K. Hahn, I.W. Husstedt, Arendt G für die Deutsche Neuro-AIDS-Arbeitsgemeinschaft (DNAA)

Erschienen in: Der Nervenarzt | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Zusammenfassung

HIV-assoziierte Polyneuropathien sind die häufigste neurologische Manifestation der HIV-Erkrankung und HIV ist weltweit eine der häufigsten Ursachen für Polyneuropathien. Das impliziert, dass HIV in Patienten mit Polyneuropathie immer differenzialdiagnostisch in Betracht gezogen werden sollte. HIV-assoziierte Polyneuropathien stellen ein breites Spektrum an Subformen dar, deren wesentliches gemeinsames Merkmal die konstante Bindung an spezifische Stadien der HIV-Erkrankung ist. Inflammatorische Neuropathien wie das Guillain-Barré-Syndrom (GBS) oder die chronisch inflammatorisch demyelinisierende Polyneuropathie (CIDP) werden typischerweise im Frühstadium der HIV-Infektion diagnostiziert, während beispielsweise die erregerbedingte Polyradikulitis eine Komplikation im AIDS-Stadium darstellt. Die distal-symmetrische Polyneuropathie als Prototyp aller Neuropathien stellt die häufigste Neuromanifestation bei Patienten mit HIV-Infektion dar. Nachfolgende Übersicht fasst die klinischen Manifestationen, die Epidemiologie, Diagnostik, Pathophysiologie und Behandlung HIV-assoziierter Polyneuropathien zusammen.

Deutsche Neuro-AIDS-Arbeitsgemeinschaft DNAA (2000) Peripheral nerve diseases and myopathies associated with HIV infection. Nervenarzt 71:442–450CrossRef

Abrams DI, Jay CA, Shade SB et al (2007) Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 68:515–521CrossRefPubMed

Anders HJ, Weiss N, Bogner JR, Goebel FD (1998) Ganciclovir and foscarnet efficacy in AIDS-related CMV polyradiculopathy. J Infect 36:29–33CrossRefPubMed

Apostolski S, McAlarney T, Quattrini A et al (1993) The gp120 glycoprotein of human immunodeficiency virus type 1 binds to sensory ganglion neurons. Ann Neurol 34:855–863CrossRefPubMed

Apostolski S, McAlarney T, Hays AP, Latov N (1994) Complement dependent cytotoxicity of sensory ganglion neurons mediated by the gp120 glycoprotein of HIV-1. Immunol Invest 23:47–52CrossRefPubMed

Bradley WG, Shapshak P, Delgado S et al (1998) Morphometric analysis of the peripheral neuropathy of AIDS. Muscle Nerve 21:1188–1195CrossRefPubMed

Brannagan TH 3rd, Zhou Y (2003) HIV-associated Guillain-Barre syndrome. J Neurol Sci 208:39–42CrossRefPubMed

Brinley FJ Jr., Pardo CA, Verma A (2001) Human immunodeficiency virus and the peripheral nervous system workshop. Arch Neurol 58:1561–1566CrossRefPubMed

Cherry CL, Gahan ME, McArthur JC et al (2002) Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat. J Acquir Immune Defic Syndr 30:271–277PubMed

10.

Cornblath DR, McArthur JC, Kennedy PG et al (1987) Inflammatory demyelinating peripheral neuropathies associated with human T-cell lymphotropic virus type III infection. Ann Neurol 21:32–40CrossRefPubMed

11.

Craddock C, Pasvol G, Bull R et al (1987) Cardiorespiratory arrest and autonomic neuropathy in AIDS. Lancet 2:16–18CrossRefPubMed

12.

Dalakas MC, Semino-Mora C, Leon-Monzon M (2001) Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2’3’-dideoxycytidine (ddC). Lab Invest 81:1537–1544PubMed

13.

Esiri MM, Morris CS, Millard PR (1993) Sensory and sympathetic ganglia in HIV-1 infection: immunocytochemical demonstration of HIV-1 viral antigens, increased MHC class II antigen expression and mild reactive inflammation. J Neurol Sci 114:178–187CrossRefPubMed

14.

Estanislao L, Carter K, McArthur J et al (2004) A randomized controlled trial of 5% lidocaine gel for HIV-associated distal symmetric polyneuropathy. J Acquir Immune Defic Syndr 37:1584–1586CrossRefPubMed

15.

Evans SR, Simpson DM, Kitch DW et al (2007) A randomized trial evaluating prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain. PLoS ONE 2:e551CrossRefPubMed

16.

Franco-Paredes C, Rebolledo P, Folch E et al (2002) Diagnosis of diffuse CD8+ lymphocytosis syndrome in HIV-infected patients. AIDS Read 12:408–413PubMed

17.

Fuller GN, Gill SK, Guiloff RJ et al (1990) Ganciclovir for lumbosacral polyradiculopathy in AIDS. Lancet 335:48–49CrossRefPubMed

18.

Gherardi RK, Chretien F, Delfau-Larue MH et al (1998) Neuropathy in diffuse infiltrative lymphocytosis syndrome: an HIV neuropathy, not a lymphoma. Neurology 50:1041–1044PubMed

19.

Griffin JW, Wesselingh SL, Griffin DE et al (1994) Peripheral nerve disorders in HIV infection. Similarities and contrasts with CNS disorders. Res Publ Assoc Res Nerv Ment Dis 72:159–182PubMed

20.

Hahn K, Arendt G, Braun JS et al (2004) A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 251:1260–1266CrossRefPubMed

21.

Hahn K, Triolo A, Hauer P et al (2007) Impaired reinnervation in HIV infection following experimental denervation. Neurology 68:1251–1256CrossRefPubMed

22.

Hahn K, Robinson B, Anderson C et al (2008) Differential effects of HIV infected macrophages on dorsal root ganglia neurons and axons. Exp Neurol 210:30–40CrossRefPubMed

23.

Hulgan T, Haas DW, Haines JL et al (2005) Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS 19:1341–1349CrossRefPubMed

24.

Itescu S, Brancato LJ, Winchester R (1989) A sicca syndrome in HIV infection: association with HLA-DR5 and CD8 lymphocytosis. Lancet 2:466–468CrossRefPubMed

25.

Jones G, Zhu Y, Silva C et al (2005) Peripheral nerve-derived HIV-1 is predominantly CCR5-dependent and causes neuronal degeneration and neuroinflammation. Virology 334:178–193CrossRefPubMed

26.

Katsarava Z, Yaldizli O, Voulkoudis C et al (2006) Pain related potentials by electrical stimulation of skin for detection of small-fiber neuropathy in HIV. J Neurol 253:1581–1584CrossRefPubMed

27.

Kazi S, Cohen PR, Williams F et al (1996) The diffuse infiltrative lymphocytosis syndrome. Clinical and immunogenetic features in 35 patients. AIDS 10:385–391CrossRefPubMed

28.

Keilbaugh SA, Prusoff WH, Simpson MV (1991) The PC12 cell as a model for studies of the mechanism of induction of peripheral neuropathy by anti-HIV-1 dideoxynucleoside analogs. Biochem Pharmacol 42:R5–R8CrossRefPubMed

29.

Keswani SC, Pardo CA, Cherry CL et al (2002) HIV-associated sensory neuropathies. AIDS 16:2105–2117CrossRefPubMed

30.

Keswani SC, Chander B, Hasan C et al (2003) FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. Ann Neurol 53:57–64CrossRefPubMed

31.

Keswani SC, Polley M, Pardo CA et al (2003) Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann Neurol 54:287–296CrossRefPubMed

32.

Kieburtz K, Simpson D, Yiannoutsos C et al (1998) A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS clinical trial group 242 protocol team. Neurology 51:1682–1688PubMed

33.

Lange DJ (1994) AAEM minimonograph #41: neuromuscular diseases associated with HIV-1 infection. Muscle Nerve 17:16–30CrossRefPubMed

34.

Lichtenstein KA, Armon C, Baron A et al (2005) Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort. Clin Infect Dis 40:148–157CrossRefPubMed

35.

Lohmoller G, Matuschke A, Goebel FD (1989) False-positive test of autonomic neuropathy in HIV infection and AIDS? Case control study of heart rate variability in 62 HIV positive patients. Med Klin 84:242–245

36.

Martin C, Solders G, Sonnerborg A, Hansson P (2000) Antiretroviral therapy may improve sensory function in HIV-infected patients: a pilot study. Neurology 54:2120–2127PubMed

37.

McArthur JC, Brew BJ, Nath A (2005) Neurological complications of HIV infection. Lancet Neurol 4:543–555CrossRefPubMed

38.

Medina DJ, Tsai CH, Hsiung GD, Cheng YC (1994) Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrob Agents Chemother 38:1824–1828PubMed

39.

Melli GaHA (2005) In vitro models of HIV-associated neuropathies differ in pathogenic site of action. 12th conference on retroviruses and opportunistic infections

40.

Miller RG, Storey JR, Greco CM (1990) Ganciclovir in the treatment of progressive AIDS-related polyradiculopathy. Neurology 40:569–574PubMed

41.

Morgello S, Estanislao L, Simpson D et al (2004) HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch Neurol 61:546–551CrossRefPubMed

42.

Moulignier A, Authier FJ, Baudrimont M et al (1997) Peripheral neuropathy in human immunodeficiency virus-infected patients with the diffuse infiltrative lymphocytosis syndrome. Ann Neurol 41:438–445CrossRefPubMed

43.

Paice JA, Ferrans CE, Lashley FR et al (2000) Topical capsaicin in the management of HIV-associated peripheral neuropathy. J Pain Symptom Manage 19:45–52CrossRefPubMed

44.

Pardo CA, McArthur JC, Griffin JW (2001) HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Syst 6:21–27CrossRefPubMed

45.

Pettersen JA, Jones G, Worthington C et al (2006) Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol 59:816–824CrossRefPubMed

46.

Polydefkis M, Yiannoutsos CT, Cohen BA et al (2002) Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy. Neurology 58:115–119PubMed

47.

Sacktor N (2002) The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 8 [Suppl 2]:115–121

48.

Schielke E, Pfister HW, Einhaupl KM (1989) Peripheral facial nerve palsy associated with HIV infection. Lancet 1:553–554CrossRefPubMed

49.

Schifitto G, McDermott MP, McArthur JC et al (2002) Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 58:1764–1768PubMed

50.

Schifitto G, McDermott MP, McArthur JC et al (2005) Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology 64:842–848PubMed

51.

Schifitto G, Yiannoutsos CT, Simpson DM et al (2006) A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy. J Neurovirol 12:328–331CrossRefPubMed

52.

Simpson DM, Dorfman D, Olney RK et al (1996) Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group. Neurology 47:1254–1259PubMed

53.

Simpson DM, McArthur JC, Olney R et al (2003) Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 60:1508–1514PubMed

54.

Tagliati M, Grinnell J, Godbold J, Simpson DM (1999) Peripheral nerve function in HIV infection: clinical, electrophysiologic and laboratory findings. Arch Neurol 56:84–89CrossRefPubMed

55.

Thornton CA, Latif AS, Emmanuel JC (1991) Guillain-Barre syndrome associated with human immunodeficiency virus infection in Zimbabwe. Neurology 41:812–815PubMed

56.

Verma A (2001) Epidemiology and clinical features of HIV-1 associated neuropathies. J Peripher Nerv Syst 6:8–13CrossRefPubMed

57.

Wernicke JF, Pritchett YL, D’Souza DN et al (2006) A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67:1411–1420CrossRefPubMed

58.

Wulff EA, Wang AK, Simpson DM (2000) HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs 59:1251–1260CrossRefPubMed

59.

Youle M, Osio M (2007) A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med 8:241–250CrossRefPubMed

Titel: HIV-assoziierte Neuropathien
verfasst von: Dr. K. Hahn
I.W. Husstedt
Arendt G für die Deutsche Neuro-AIDS-Arbeitsgemeinschaft (DNAA)
Publikationsdatum: 01.04.2010
Verlag: Springer-Verlag
Erschienen in: Der Nervenarzt / Ausgabe 4/2010
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-010-2931-x

Neu in den Fachgebieten Neurologie und Psychiatrie

25.04.2024 | Hypotonie | Nachrichten

Springer Medizin

HIV-assoziierte Neuropathien

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

Schlaganfall bei Tumorpatienten

Mitteilungen der DGPPN 4/2010

Mitteilungen der Schlaganfallgesellschaft 4/2010

Kardiologische Diagnostik nach zerebraler Ischämie

Umstellungen zwischen Lamotrigin-Präparaten bei Epilepsiepatienten

Bilaterale Media- und Posteriorinfarkte bei Takotsubo-Kardiomyopathie

Neu in den Fachgebieten Neurologie und Psychiatrie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe